Epizyme to Present at the Jefferies 2017 London Healthcare Conference

CAMBRIDGE, Mass., Nov. 09, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present a company overview at the Jefferies 2017 London Healthcare Conference on Thursday, Nov. 16, 2017 at 11:20 a.m. GMT. The conference is being held Nov. 15-16, 2017 at the Waldorf Hilton, Aldwych, London.

To access the live webcast of Epizyme's presentation, please visit the Events & Presentations page within the Investor page of the website at www.epizyme.com. A replay of the webcast will be available on the Epizyme website for 60 days following the conference.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. Using the Company's proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com.

Contacts:
Cheya Pope, Epizyme, Inc.
[email protected]
617-229-7561

Monique Allaire, THRUST IR
[email protected]
617-895-9511